HER2/neu-directed therapy for biliary tract cancer

被引：0

作者：

Milind Javle

Chaitanya Churi

HyunSeon C. Kang

Rachna Shroff

Filip Janku

Rakesh Surapaneni

Mingxin Zuo

Christian Barrera

Humaid Alshamsi

Sunil Krishnan

Lopa Mishra

Robert A. Wolff

Ahmed O. Kaseb

Melanie B. Thomas

Abby B. Siegel

机构：

[1] The University of Texas MD Anderson Cancer Center,Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine

[2] The University of Texas MD Anderson Cancer Center,Department of Diagnostic Radiology, Division of Diagnostic Imaging

[3] The University of Texas MD Anderson Cancer Center,Department of Investigational Cancer Therapeutics, Division of Cancer Medicine

[4] Scott & White Clinic,Department of Radiation Oncology, Division of Radiation Oncology

[5] The University of Texas MD Anderson Cancer Center,Department of Gastroenterology

[6] The University of Texas MD Anderson Cancer Center,Departments of Medicine and Surgery

[7] Gibbs Cancer Center & Research Institute,undefined

[8] Columbia University,undefined

来源：

Journal of Hematology & Oncology | / 8卷

关键词：

Receptor; ErbB-2; Gallbladder neoplasms; Cancer of the biliary tract;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Overexpression of HER2/neu as a Prognostic Value in Iranian Women With Early Stage Breast Cancer; A Single Institute Study
Mahyari, Hanifeh Mirtavoos
Khosravi, Adnan
Mahyari, Zeinab Mirtavoos
Monfared, Zahra Esfahani
Khosravi, Negin
IRANIAN RED CRESCENT MEDICAL JOURNAL, 2014, 16 (11)
[32] Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy
Ebinc, Senar
Oruc, Zeynep
Sezgin, Yasin
Karhan, Ogur
Bilen, Erkan
Yerlikaya, Halis
Kalkan, Ziya
Urakci, Zuhat
Kucukoner, Mehmet
Kaplan, Muhammet Ali
Isikdogan, Abdurrahman
FUTURE ONCOLOGY, 2022, 18 (30) : 3399 - 3408
[33] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
Van Raemdonck, Elisa
Floris, G.
Berteloot, P.
Laenen, A.
Vergote, I.
Wildiers, H.
Punie, K.
Neven, P.
BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
[34] Oncogenic HER2 fusions in gastric cancer
Yu, De-Hua
Tang, Lili
Dong, Hua
Dong, Zhengwei
Zhang, Lianhai
Fu, Jiangang
Su, Xinying
Zhang, Tianwei
Fu, Haihua
Han, Lu
Xie, Liang
Chen, Hao
Qian, Ziliang
Zhu, Guanshan
Wang, Jia
Ye, Qingqing
Zhang, Jingchuan
Yin, Xiaolu
Zhang, Xiaolin
Ji, Jiafu
Ji, Qunsheng
JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
[35] Differences between the efficacy of HER2(2+)/FISH-positive and HER2 (3+) in breast cancer during dual-target neoadjuvant therapy
Chen, Wei
Li, Fen-Xiang
Lu, Da-Lin
Jiang, Jun
Li, Junjie
BREAST, 2023, 71 : 69 - 73
[36] HER2/neu and Ki-67 as prognostic factors in serous type ovarian carcinoma
Dewi, I. Gusti Ayu Sri Mahendra
Susraini, Anak Agung Ayu Ngurah
Ekawati, Ni Putu
BALI MEDICAL JOURNAL, 2020, 9 (02) : 567 - 571
[37] HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Morsberger, Laura
Pallavajjala, Aparna
Long, Patty
Hardy, Melanie
Park, Rebecca
Parish, Rebecca
Nozari, Azin
Zou, Ying S.
CANCER CELL INTERNATIONAL, 2022, 22 (01)
[38] Biology of HER2 and its importance in breast cancer
Yarden, Y
ONCOLOGY, 2001, 61 : 1 - 13
[39] HER2 mRNA transcript quantitation in breast cancer
Meehan, K.
Clynick, B.
Mirzai, B.
Maslen, P.
Harvey, J. M.
Erber, W. N.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (05) : 606 - 615
[40] Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients
Peng, Zhi
Liu, Yi
Li, Yanyan
Zhang, Xiaotian
Zhou, Jun
Lu, Ming
Li, Qingqing
Shen, Lin
BIOMARKERS IN MEDICINE, 2014, 8 (05) : 663 - 670

← 1 2 3 4 5 →